Amyris (AMRS) Misses Q2 EPS by 5c

Amyris (: AMRS) reported Q2 EPS of ($0.34), $0.05 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $78.68 million.

For earnings history and earnings-related data on Amyris (AMRS) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Morgan Stanley Downgrades Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) to Equalweight
• UBS Upgrades Solstice Advanced Materials Inc. (SOLS) to Buy